$4550
The influenza vaccines market was valued at US$ 7,478.53 million in 2021 and it is expected to grow US$ 12,272.49 million by 2028; with a CAGR of 7.4% from 2022 to 2028
Influenza is a contagious respiratory infection caused due to influenza virus. Influenza is noticed by fever, cough, muscle and joint pain, headache, and severe weakness. Illness due to influenza varies from mild to severe, sometimes leading to death. According to the World Health Organization (WHO), 2018, influenza cases related hospitalization ranges from 3-5 million cases for severe illness, whereas deaths related to influenza are about 290,000 to 650,000. Vaccines are adviced for the prevention of influenza infections. The rapid spread of influenza virus epidemics worldwide propels demands for developing an efficient influenza vaccine. A strong product pipeline is a key factor driving the market's growth during the forecast period.
The influenza vaccines market is analyzed on the basis of vaccine type, virus type, technology, route of administration, target group, and geography. By geography, the market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The influenza vaccines market report offers insights and in-depth analysis of the market, emphasizing market trends, technological advancements, market dynamics, and the competitive analysis of the leading market players.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Influenza Vaccines Market: Strategic Insights
Market Size Value in US$ 7,478.53 Million in 2021 Market Size Value by US$ 12,272.49 Million by 2028 Growth rate CAGR of 7.4% from 2022 to 2028 Forecast Period 2022-2028 Base Year 2021
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Influenza Vaccines Market: Strategic Insights

Market Size Value in | US$ 7,478.53 Million in 2021 |
Market Size Value by | US$ 12,272.49 Million by 2028 |
Growth rate | CAGR of 7.4% from 2022 to 2028 |
Forecast Period | 2022-2028 |
Base Year | 2021 |

Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Lucrative Regions for Influenza Vaccines Market
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Market Insights
Increasing Investment by Top Market Players and Governments to Drive Influenza Vaccines Market
Market players and governments worldwide are increasing their investments in vaccine development and immunization. For instance, In March 2021, Sanofi announced an approximately US$ 925 million investments in a new vaccine manufacturing plant at its pre-existing site in Toronto and Canada. Investments in the new facility will provide additional antigen and filling capacity for Sanofi's FLUZONE high-dose quadrivalent influenza vaccines, increasing availability in Canada, the US, and Europe in the years to come.
- In April 2021, 3 levels of government - federal, provincial and municipal - supported Sanofi Pasteur in building an "end-to-end" influenza vaccines factory in Toronto. The partners will invest nearly US$ 1 billion to get the site up and running, slated for 2027. Paris-based Sanofi, for its part, will invest more than US$ 55 million, create 165 new eligible jobs, and maintain another 1,100. The federal government is investing US$ 55 million, while the Ontario government is contributing US$ 55 million, making it a US$ 925 million project. In addition, Sanofi will also invest at least US$ 79 million annually over 8 years to fund research and development in Canada.
- In November 2020, Vaccine maker Seqirus planned to invest US$ 800 million in a significant Australian vaccine manufacturing center. The new plant will be located at Tullamarine in the business district of Melbourne Airport and is expected to come online in 2026, Seqirus said. The company did not disclose the desired square meter area in a statement.
- In March 2022, The Australian Government announced a US$ 100 million investments in a seasonal flu vaccine. The objective of this investment is to protect people from influenza and COVID-19 to minimize its impact on healthcare in Australia.
- In June 2021, The European Investment Bank signed a US$ 30.55 million global vaccine distribution agreement with biotech company Univercells to mass produce the COVID-19 vaccine at a new Belgian site. It helped build other vaccine factories around the world. In April 2022, the Bank provided a US$ 15.27 million loan to Italian biomedical research company IRBM to expand its vaccine production capacity and strengthen research on coronaviruses and other diseases.
Thus, the increase in investment by top market players and governments across the globe is bolstering the influenza vaccines market.
Vaccine Type Insights
Based on vaccine type, the global influenza vaccines market is segmented into quadrivalent vaccines and trivalent vaccines. The quadrivalent segment held a larger share of the market in 2021. The same segment is expected to grow faster over the forecast period. The increasing product approvals and rising product launches for market expansion are among the primary drivers of the quadrivalent vaccine segment growth.
Influenza Vaccines Market, by Vaccine Type – during 2022–2028
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Virus Type Insights
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Based on virus type, the global influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger market share in 2021. The same is expected to grow faster over the forecast period due to the increasing prevalence of influenza type A. The market growth of the influenza virus type A segment is attributed to it being the most common form of influenza. It can infect animals, although illnesses associated with this type of flu are more common.
Product Approvals and Collaborations are highly adopted strategies by influenza vaccines market players. A few of the recent key market developments are listed below:
- In July 2022, The US Food and Drug Administration (FDA) approved Sanofi's licensure request for vaccine approval for the upcoming 2022-2023 flu season, including Fluzone High-Dose Quadrivalent (Influenza Vaccine), Flublok Quadrivalent (Influenza Vaccine), and Fluzone Quadrivalent (Influenza Vaccine). This approval comes on the heels of the CDC's Advisory Committee on Immunization Practices (ACIP) preferential recommendation for adults 65+ including Fluzone High-Dose Quadrivalent and Flublok Quadrivalent.
- In July 2022, GSK announced an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine).
The COVID-19 pandemic is expected to boost the global influenza vaccines market growth, owing to the increasing demand for influenza vaccines during a pandemic. According to data published by the Centers for Disease Control and Prevention in November 2021, the overall influenza vaccine administration in the US increased by 9.0% from September to December 2020, with more doses administered to adolescents and adults than in September to December 2018 and 2019.
Influenza Vaccines– Market Segmentation
The global influenza vaccines market is analyzed on the basis of vaccine type, virus type, technology, route of administration, target group, and geography. Based on vaccine type, the market is segmented into quadrivalent vaccines and trivalent vaccines. Based on virus type, the market is segmented into influenza virus type A and influenza virus type B. Based on technology, the market is bifurcated into egg-based and cell-based. Based on route of administration, the market is segmented into injection and nasal spray. Based on target group, the market can be segmented into infants, children, adults, and elderly. By geography, the influenza vaccines market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.
Company Profiles
Moderna, Inc.; SEQIRUS; Sanofi; GlaxoSmithKline plc; Hualan Biological Engineering Inc.; Emergent BioSolutions Inc.; Mitsubishi Chemical Group Corporation; Serum Institute of India Pvt. Ltd; Mylan N. V.; and AstraZeneca are the key companies operating in the influenza vaccines market. The companies are taking up product innovation strategies to meet the evolving customer demands globally, allowing them to maintain their brand name in the global influenza vaccines market

Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Vaccine Type, Virus Type, Technology, Route of Administration, and Target Group

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, RoAPAC, RoE, RoMEA, RoSAM, Saudi Arabia, South Africa, South Korea, Spain, Switzerland, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The quadrivalent segment held the larger share of the market in the global influenza vaccines market contributing a market share of 88.36% in 2022.
The Asia Pacific is expected to be the fastest-growing region in the influenza vaccines market over the forecast period due to growing investments from international players in China and India, increasing disposable income, and influenza cases in these regions will show promising growth in the influenza vaccines market.
The influenza vaccines market is estimated to be valued at US$ 7,478.53 million in 2021.
The influenza vaccines market is expected to be valued at US$ 12,272.49 million in 2028.
The CAGR value of the influenza vaccines market during the forecasted period of 2022-2028 is 7.4%.
The influenza vaccines market majorly consists of the players, such as Moderna, Inc.; SEQIRUS; Sanofi; GlasoSmithKline plc; Hualan Biological Engineering Inc.; Emergent Biosolutions Inc.; Mitsubishi Chemical Group Corporation; Serum Institute of India Pvt. Ltd; Mylan N. V.; and AstraZeneca
The factors that are driving the growth of the influenza vaccines market are increase in government support to promote influenza vaccination and increasing investment by top market players and governments.
Influenza virus causes flu which is a contagious respiratory illness that infects nose, throat and lungs. It can mild or severe and sometimes may lead to death. Flu vaccination every year can help in preventing flu. However, this can be deadly, especially in high-risk groups. Aged population, pregnant women and people with one or more chronic disease or with weak immune systems are at high risk. Influenza vaccines/flu shots protect against the four influenza viruses’ subtypes that are most common. Most of the influenza vaccines are “flu shots†given with a needle, usually in the arm, but nasal spray flu vaccine are also available.
The List of Companies - Influenza Vaccines Market
- Moderna, Inc.
- SEQIRUS
- Sanofi
- GlaxoSmithKline plc.
- Hualan Biological Engineering Inc.
- Emergent BioSolutions Inc.
- Mitsubishi Chemical Group Corporation
- Serum Institute of India Pvt. Ltd
- MYLAN N.V.
- AstraZeneca
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports

Oct 2022
US Pharmacy Management System Market
Size and Forecasts (2022 - 2030), Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Component (Solutions and Services), Deployment (Cloud-based and On-premise), Size of Pharmacies (Small- and Medium-sized Pharmacies, and Large Pharmacies), End User (In-patient Pharmacies, Outpatient Pharmacies)

Oct 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography

Oct 2022
Drug Delivery Market
Forecast to 2028 - Global Analysis By Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End User)

Oct 2022
Enteral and Parenteral Medical Nutrition Market
Forecast to 2028 - Global Analysis by Indication [Elderly, Gastrointestinal Disorders (IBD, IBS, and Others), Diabetes, Cancer, Respiratory Disorders, Alzheimer's Disease, Dementia, Renal Disease, Liver Failure, Post COVID-19, and Other Indications], Nutrition Type (Supplemental and Sole–Source), Form (Liquid, Powder, and Semi–Solid), Product Type (General and Disease–Specific), Route of Administration (Oral, Tube Feed, and Parenteral), Age Group (Above 60 Years, 18–60 Years, 3–18 Years, and Below 3 Years), and Distribution Channel (Hospital Pharmacies, Retail Stores, E-Commerce, and Others)

Oct 2022
CIN & HR-HPV Treatment Market
Forecast to 2028 - Global Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)

Oct 2022
Pharmaceutical Fluid Handling Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Offering (Equipment & Solutions and Services), Tubing (Thermoplastic Elastomers, Polyvinyl Chloride, and Silicone), Application (Fluid Handling & Management, Fluid Preparation, Integration & Automation, Buffer Management, and Others), Usage (Cough Syrup, Intravenous Product, Complex Active Pharmaceutical Ingredients, and Others), and End User (Biotechnology Companies, Pharmaceutical & Medical Companies, and Others)

Oct 2022
Enteral Medical Nutrition Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]

Oct 2022
Glycomic Therapeutics Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), and Mode of Action [Inhibits Neuraminidase; Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate; Erythropoietin & Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 & 3; Beta & Gamma Interferons; and Others]